Overall, these results prove that CD123 aptamer ZW25 is a potential targeting molecule in AML-targeted therapy, and CD123 aptamers-mediated targeted drug delivery systems are great options for AML-targeted therapy. The gene discussed is IL3RA; the disease is acute myeloid leukemia.